Adaptive Biotechnologies Corp (ADPT) stock
ADPTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 12/30322% above fair value
$29.04−0.44 (-1.49%)
Close on Nov 13, 2026Market cap $4.63BP/E –Yield –
Adaptive Biotechnologies gross margin
Gross margin is gross profit as a percentage of revenue.
Adaptive Biotechnologies's gross margin for the twelve months ending Sep 30, 2026 was 74.2%. For fiscal 2025 it was 74.2%, against 59.7% the year before. The highest annual figure on record is 77.1% in fiscal 2020.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 74.2% | +14.5 |
| FY2024 | Dec 31, 2024 | 59.7% | +4.1 |
| FY2023 | Dec 31, 2023 | 55.6% | −13.1 |
| FY2022 | Dec 31, 2022 | 68.7% | +0.7 |
| FY2021 | Dec 31, 2021 | 68.1% | −9.0 |
| FY2020 | Dec 31, 2020 | 77.1% | +3.3 |
| FY2019 | Dec 31, 2019 | 73.8% | +9.2 |
| FY2018 | Dec 31, 2018 | 64.7% | +5.4 |
| FY2017 | Dec 31, 2017 | 59.2% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 76.2% | −4.4 |
| Q2 FY2026 | Jun 30, 2026 | 71.8% | +2.4 |
| Q1 FY2026 | Mar 31, 2026 | 73.6% | +6.0 |
| Q4 FY2025 | Dec 31, 2025 | 74.6% | +12.6 |
| Q3 FY2025 | Sep 30, 2025 | 80.7% | +16.6 |
| Q2 FY2025 | Jun 30, 2025 | 69.4% | +14.2 |
| Q1 FY2025 | Mar 31, 2025 | 67.6% | +10.7 |
| Q4 FY2024 | Dec 31, 2024 | 62.0% | +4.8 |
| Q3 FY2024 | Sep 30, 2024 | 64.1% | +15.1 |
| Q2 FY2024 | Jun 30, 2024 | 55.3% | −8.1 |
| Q1 FY2024 | Mar 31, 2024 | 56.9% | +6.5 |
| Q4 FY2023 | Dec 31, 2023 | 57.2% | −12.8 |
| Q3 FY2023 | Sep 30, 2023 | 49.0% | −19.9 |
| Q2 FY2023 | Jun 30, 2023 | 63.4% | −6.3 |
| Q1 FY2023 | Mar 31, 2023 | 50.4% | −15.5 |
| Q4 FY2022 | Dec 31, 2022 | 69.9% | +7.8 |
| Q3 FY2022 | Sep 30, 2022 | 68.8% | +4.8 |
| Q2 FY2022 | Jun 30, 2022 | 69.7% | −2.3 |
| Q1 FY2022 | Mar 31, 2022 | 65.8% | −8.2 |
| Q4 FY2021 | Dec 31, 2021 | 62.2% | −17.2 |
| Q3 FY2021 | Sep 30, 2021 | 64.0% | −12.9 |
| Q2 FY2021 | Jun 30, 2021 | 72.0% | −4.6 |
| Q1 FY2021 | Mar 31, 2021 | 74.0% | −0.4 |
| Q4 FY2020 | Dec 31, 2020 | 79.4% | +4.0 |
| Q3 FY2020 | Sep 30, 2020 | 77.0% | −1.5 |
| Q2 FY2020 | Jun 30, 2020 | 76.6% | +2.5 |
| Q1 FY2020 | Mar 31, 2020 | 74.4% | +13.8 |
| Q4 FY2019 | Dec 31, 2019 | 75.4% | +6.1 |
| Q3 FY2019 | Sep 30, 2019 | 78.5% | +9.7 |
| Q2 FY2019 | Jun 30, 2019 | 74.1% | +17.7 |
| Q1 FY2019 | Mar 31, 2019 | 60.6% | – |
| Q4 FY2018 | Dec 31, 2018 | 69.3% | – |
| Q3 FY2018 | Sep 30, 2018 | 68.8% | – |
| Q2 FY2018 | Jun 30, 2018 | 56.4% | – |
See a number that looks wrong?